|
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer Clinical research trials and Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer. Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer  Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
For Condition: recurrent prostate cancer,stage 1 prostate cancer,adenocarcinoma of the prostate,stage 3 prostate cancer,stage 2 prostate cancer,stage 4 prostate cancer
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Calcitriol may help prostate cancer cells develop into normal cells. Zoledronate may delay or prevent the formation of bone metastases . Combining calcitriol and zoledronate may be an effective treatment for progressive prostate cancer. PURPOSE: Phase I trial to study the effectiveness of combining calcitriol with zoledronate in treating patients who have progressive prostate cancer.
Details: OBJECTIVES: I. Determine the maximum tolerated dose of calcitriol administered with zoledronate in patients with progressive prostate cancer. II. Assess the effects of this regimen on calcium homeostasis and bone turnover in this patient population. III. Assess changes in PSA in patients treated with this regimen. IV. Determine other antitumor effects of this regimen in these patients. PROTOCOL OUTLINE: This is a dose-escalation study of calcitriol. Patients receive oral calcitriol weekly for 3 consecutive days and zoledronate IV monthly. Treatment continues in the absence of unacceptable toxicity or disease progression. Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 1 year.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Histologically confirmed prior localized adenocarcinoma of the prostate that has undergone definitive radiation or surgery and demonstrates progression biochemically with all of the following: - Baseline PSA at least 4 ng/mL - At least a 50% increase in PSA over at least 3 determinations taken at more than 2 week intervals - No radiographically evident disease - Neoadjuvant hormonal therapy prior to radical prostatectomy or radiotherapy allowed - Treatment in an intermittent approach allowed if off therapy for at least 12 weeks OR Histologically confirmed androgen-independent adenocarcinoma of the prostate with all of the following: - Progression on primary hormonal treatment (e.g., orchiectomy, estrogen therapy, gonadotropin-releasing hormone analog with or without an antiandrogen) with either new osseous lesions in bone, a greater than 25% increase in bidimensionally measurable tumor mass, or rising PSA values (rising PSA on any 3 determinations taken at at least weekly intervals, to greater than 50% above baseline PSA) despite castrate levels of testosterone (no greater than 30 ng/mL) - If receiving antiandrogen as part of primary hormonal therapy, must meet criteria above for progression after discontinuation of antiandrogen - No change in hormonal therapy (including prednisone or dexamethasone) within the past 2 weeks - If no prior surgical orchiectomy, must continue on medical therapies to maintain castrate levels of testosterone - Prior chemotherapy, palliative radiotherapy, or radioisotope treatment allowed --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy and recovered - No concurrent chemotherapy Endocrine therapy: - See Disease Characteristics - Recovered from prior endocrine therapy Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered - No concurrent radiotherapy to sole measurable lesion Surgery: - See Disease Characteristics - Recovered from prior surgery - No concurrent surgery to sole measurable lesion Other: No other concurrent cholecalciferol --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 70-100% Life expectancy: At least 3 months Hematopoietic: - WBC at least 3,500/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin less than 2.0 mg/dL OR - SGOT less than 3 times upper limit of normal Renal: - Creatinine less than 1.5 mg/dL OR - Creatinine clearance at least 60 mL/min - No history of nephrolithiasis - Must have 2 functioning kidneys Cardiovascular: No New York Heart Association class III or IV heart disease Pulmonary: No severe debilitating pulmonary disease Metabolic: No pre-existing endocrine or metabolic disorders that impact calcium regulatory axis including hypercalcemia (ionized serum calcium greater than 5.3 mg/dL or total calcium greater than 10.5 mg/dL) or hypercalciuria (greater than 300 mg urinary calcium/24 hours) Other: - No active secondary malignancy except nonmelanoma skin cancer - Must maintain low calcium diet (less than 800 mg calcium daily) - No uncontrolled serious active infection - No history of malabsorption disorders - No history of inflammatory bowel disease
Total Enrollment:
Location and Contact Information:
Overall Study Official:
MichaelMorris, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000067612; MSKCC-99073,NCI-H00-0048
Study Start Date: October 1999
Record last reviewed: May 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004928
Other Stage 3 Prostate Cancer Studies:
1. Hormone Therapy in Treating Men With Stage IV Prostate Cancer
2. Lycopene in Treating Patients With Metastatic Prostate Cancer
3. Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
4. Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
5. Radiation Therapy in Treating Patients With Bone Metastases From Breast or Prostate Cancer
Related Studies:
Other stage 3 prostate cancer Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Calcitriol and Zoledronate in Treating Patients With Progressive Prostate Cancer
|
|
|
|
|
|
|
|
